Manages mastocytosis. ANDA 202745, held by Micro Labs Ltd India. Cromolyn Sodium.
As of Nov 21, 2026, ANDA 202745 (Cromolyn Sodium), held by Micro Labs Ltd India, was first approved by FDA on Apr 4, 2013, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Cromolyn Sodium Oral Solution (Concentrate) 100 mg/5 mL is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 4, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cromolyn Sodium100MG/5ML · concentrate;oral | Cromolyn Sodium | Rx |
| Dec 5, 2023 | Supplement 10Manufacturing | Approved | None posted |
| Nov 14, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 4, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters